KMT2D and cancer: In this study, we found that upregulation of KMT2D aggravates malignant behaviors in a patient-derived organoid (PDO) platform and in in vitro and in vivo cancer cell lines by mediating the transcription of CTNNB1 in cooperation with MEF2A thus sustaining stem-like properties and Wnt/β-catenin signaling.